Daiichi Sankyo's edoxaban meets primary endpoint

|By:, SA News Editor

Daiichi Sankyo's edoxaban meets its primary endpoint of non-inferiority to warfarin in a Phase 3 study of more than 8K patients with either acute symptomatic deep vein thrombosis, DVT, pulmonary embolism, or both.

When administered after heparin therapy, edoxaban was just as effective at preventing new blood clots as warfarin and caused less bleeding.

"Edoxaban will face intense competition when it reaches the market," one analyst tells Bloomberg, adding that if approved for both venous thromboembolism and atrial fibrillation, edoxaban could see sales of ¥40B by year-end 2018.

Expected to face competition from edoxaban: Pfizer (PFE) and Bristol-Myers' (BMY) Eliquis, Boehringer Ingelheim's Pradaxa, and Johnson & Johnson (JNJ) and Bayer's (BAYZF.PK) Xarelto.

See also: Goldman says edoxaban poses limited threat to Eliquis.